ALLISON STEPHENSON: Open Payments
NPI 1962893891 · KYLE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,575 in 185 payments from 22 companies in 2025. Trend: 2023 $835 · 2024 $3,187 · 2025 $3,575
Food & beverage: $3,575
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 55 | $864 |
| QOL Medical, LLC | 14 | $448 |
| Janssen Biotech, Inc. | 17 | $281 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $210 |
| Celltrion USA Inc. | 11 | $201 |
| Gilead Sciences, Inc. | 9 | $161 |
| Ardelyx, Inc. | 10 | $156 |
| Janssen Scientific Affairs, LLC | 1 | $145 |
| Aimmune Therapeutics, Inc. | 10 | $138 |
| Intercept Pharmaceuticals, Inc. | 10 | $135 |
Products named: Sucraid, TREMFYA, LINZESS, DUPIXENT, MAVYRET, VEGZELMA, XIFAXAN, IBSRELA.
Industry payments across TX — which companies pay providers there.
